Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

A multi-omics approach reveals mechanisms of nanomaterial toxicity and structure-activity relationships in alveolar macrophages.

Bannuscher A, Karkossa I, Buhs S, Nollau P, Kettler K, Balas M, Dinischiotu A, Hellack B, Wiemann M, Luch A, von Bergen M, Haase A, Schubert K.

Nanotoxicology. 2020 Mar;14(2):181-195. doi: 10.1080/17435390.2019.1684592. Epub 2019 Nov 27.

PMID:
31774342
2.

An in-depth multi-omics analysis in RLE-6TN rat alveolar epithelial cells allows for nanomaterial categorization.

Karkossa I, Bannuscher A, Hellack B, Bahl A, Buhs S, Nollau P, Luch A, Schubert K, von Bergen M, Haase A.

Part Fibre Toxicol. 2019 Oct 25;16(1):38. doi: 10.1186/s12989-019-0321-5.

3.

Analyzing expression and phosphorylation of the EGF receptor in HNSCC.

Kriegs M, Clauditz TS, Hoffer K, Bartels J, Buhs S, Gerull H, Zech HB, Bußmann L, Struve N, Rieckmann T, Petersen C, Betz CS, Rothkamm K, Nollau P, Münscher A.

Sci Rep. 2019 Sep 19;9(1):13564. doi: 10.1038/s41598-019-49885-5.

4.

Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells.

Kurze AK, Buhs S, Eggert D, Oliveira-Ferrer L, Müller V, Niendorf A, Wagener C, Nollau P.

Cell Commun Signal. 2019 Aug 27;17(1):107. doi: 10.1186/s12964-019-0420-9.

5.

Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair.

Seoane M, Buhs S, Iglesias P, Strauss J, Puller AC, Müller J, Gerull H, Feldhaus S, Alawi M, Brandner JM, Eggert D, Du J, Thomale J, Wild PJ, Zimmermann M, Sternsdorf T, Schumacher U, Nollau P, Fisher DE, Horstmann MA.

Oncogene. 2019 May;38(19):3616-3635. doi: 10.1038/s41388-018-0661-x. Epub 2019 Jan 16.

6.

Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.

Siekmann IK, Dierck K, Prall S, Klokow M, Strauss J, Buhs S, Wrzeszcz A, Bockmayr M, Beck F, Trochimiuk M, Gottschling K, Martens V, Khosh-Naucke M, Gerull H, Müller J, Behrmann L, Blohm M, Zahedi RP, Jeremias I, Sickmann A, Nollau P, Horstmann MA.

Blood Adv. 2018 Oct 9;2(19):2554-2567. doi: 10.1182/bloodadvances.2018020693.

7.

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.

Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M.

Blood. 2018 Apr 12;131(15):1755-1758. doi: 10.1182/blood-2017-06-788166. Epub 2018 Feb 23. No abstract available.

PMID:
29475960
8.

SH2 Domain Histochemistry.

Buhs S, Nollau P.

Methods Mol Biol. 2017;1555:535-545. doi: 10.1007/978-1-4939-6762-9_31.

PMID:
28092054
9.

Identification of Tyrosine Phosphorylated Proteins by SH2 Domain Affinity Purification and Mass Spectrometry.

Buhs S, Gerull H, Nollau P.

Methods Mol Biol. 2017;1555:407-418. doi: 10.1007/978-1-4939-6762-9_23.

PMID:
28092046
10.

Reverse phase protein arrays enable glioblastoma molecular subtyping.

Hutter G, Sailer M, Azad TD, von Bueren AO, Nollau P, Frank S, Tostado C, Sarvepalli D, Ghosh A, Ritz MF, Boulay JL, Mariani L.

J Neurooncol. 2017 Feb;131(3):437-448. doi: 10.1007/s11060-016-2316-5. Epub 2016 Nov 17.

PMID:
27858266
11.

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.

Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P, Bumm T, Böttcher S, Bargou RC, Binder M.

Blood. 2017 Jan 5;129(1):100-104. doi: 10.1182/blood-2016-05-718395. Epub 2016 Oct 26.

PMID:
27784674
12.

Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma.

Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Dierlamm J, Gerull H, Nollau P, Klapper W, Dreyling M, Binder M, Trepel M.

Haematologica. 2016 Sep;101(9):e378-81. doi: 10.3324/haematol.2016.141929. No abstract available.

13.

The Protein Tyrosine Phosphatase Rptpζ Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice.

Baldauf C, Jeschke A, Kanbach V, Catala-Lehnen P, Baumhoer D, Gerull H, Buhs S, Amling M, Nollau P, Harroch S, Schinke T.

PLoS One. 2015 Sep 11;10(9):e0137745. doi: 10.1371/journal.pone.0137745. eCollection 2015.

14.

LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.

Frietsch JJ, Kastner C, Grunewald TG, Schweigel H, Nollau P, Ziermann J, Clement JH, La Rosée P, Hochhaus A, Butt E.

Oncotarget. 2014 Jul 30;5(14):5257-71.

15.

Time-resolved characterization of cAMP/PKA-dependent signaling reveals that platelet inhibition is a concerted process involving multiple signaling pathways.

Beck F, Geiger J, Gambaryan S, Veit J, Vaudel M, Nollau P, Kohlbacher O, Martens L, Walter U, Sickmann A, Zahedi RP.

Blood. 2014 Jan 30;123(5):e1-e10. doi: 10.1182/blood-2013-07-512384. Epub 2013 Dec 9.

PMID:
24324209
16.

Functional interaction of SCAI with the SWI/SNF complex for transcription and tumor cell invasion.

Kreßner C, Nollau P, Grosse R, Brandt DT.

PLoS One. 2013 Aug 2;8(8):e69947. doi: 10.1371/journal.pone.0069947. Print 2013.

17.

Deciphering of ADP-induced, phosphotyrosine-dependent signaling networks in human platelets by Src-homology 2 region (SH2)-profiling.

Schweigel H, Geiger J, Beck F, Buhs S, Gerull H, Walter U, Sickmann A, Nollau P.

Proteomics. 2013 Mar;13(6):1016-27. doi: 10.1002/pmic.201200353. Epub 2013 Feb 18.

PMID:
23322602
18.

Protein domain histochemistry (PDH): binding of the carbohydrate recognition domain (CRD) of recombinant human glycoreceptor CLEC10A (CD301) to formalin-fixed, paraffin-embedded breast cancer tissues.

Nollau P, Wolters-Eisfeld G, Mortezai N, Kurze AK, Klampe B, Debus A, Bockhorn M, Niendorf A, Wagener C.

J Histochem Cytochem. 2013 Mar;61(3):199-205. doi: 10.1369/0022155412474823. Epub 2012 Dec 28.

19.

Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling.

Machida K, Khenkhar M, Nollau P.

Genes Cancer. 2012 May;3(5-6):353-61. doi: 10.1177/1947601912459048.

20.

Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression.

Otto B, Gruner K, Heinlein C, Wegwitz F, Nollau P, Ylstra B, Pantel K, Schumacher U, Baumbusch LO, Martin-Subero JI, Siebert R, Wagener C, Streichert T, Deppert W, Tolstonog GV.

Int J Cancer. 2013 Mar 15;132(6):1300-10. doi: 10.1002/ijc.27783. Epub 2012 Sep 26.

Supplemental Content

Loading ...
Support Center